Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

Prognostic value of DNA aneuploidy in gastric cancer: a meta-analysis of 3449 cases

Authors: Jing Xu, Ruolin Zhu, Lulu Fan, Shangqing Ge, Wei Wei, Xiaoqiu Li, Liangshan Da, Zhenya Jia, Zhiyan Zhao, Jie Ning, Jie Da, Wanren Peng, Kangsheng Gu, Guoping Sun

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

DNA aneuploidy has attracted growing interest in clinical practice. Nevertheless, its prognostic value in gastric cancer patients remains controversial. This meta-analysis aims to explore the impact of DNA ploidy status on the survival of gastric cancer patients.

Methods

We used PubMed and Web of Science databases to retrieve relevant articles. The correlation between DNA aneuploidy and the clinicopathological features of gastric cancer, such as stage, depth of invasion (T), lymph node metastasis (N), distant metastasis (M), differentiation (G), tumor types (Lauren classification) and overall survival (OS) were evaluated. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were collected carefully from each article OS was presented with HRs. The relationships between DNA aneuploidy and each characteristic were analyzed using risk ratios (RR) and a 95% confidence interval (CI). Significance was established using P < 0.05. Funnel plot was conducted to detect the publication bias.

Results

After careful selection, 25 studies involving 3449 cases were eligible for further analyses. Patients with DNA aneuploidy were considered at risk of more advanced stages (stage III-IV vs. stages I-II, RR = 1.23; 95% CI, 1.07 to 1.42; P = 0.003), lymph node metastasis (N+ vs. N-: RR = 1.43; 95% CI, 1.12 to 1.82, P = 0.004), and intestinal tumor type (intestinal vs. diffuse: RR = 1.45; 95% CI, 1.02 to 2.06; P = 0.04). And an adverse relation was observed between DNA aneuploidy and tumor differentiation. While no association was found between DNA aneuploidy and distant metastasis (P = 0.42) nor depth of tumor invasion (P = 0.86). Regarding overall survival, aneuploid tumors were associated with worse survival in all patients (P < 0.00001).

Conclusions

We found that DNA aneuploidy was an important predictor for gastric cancer patients, and should be used as a potential biomarker for further classification in gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202.CrossRef
2.
3.
Matboli M, El-Nakeep S, Hossam N, et al. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: a review of the literature. World J Gastroenterol. 2016;22(26):5896.PubMedPubMedCentralCrossRef
4.
Bignold LP, Coghlan B, Jersmann H. David Paul Hansemann: chromosomes and the origin of the cancerous features of tumor cells. Anal Cell Pathol. 2009;31(1):61.
5.
6.
7.
Choma D, Daures JP, Quantin X, et al. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. Br J Cancer. 2001;85(1):14.PubMedPubMedCentralCrossRef
8.
Laubert T, Freitag-Wolf S, Linnebacher M, et al. Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer—a meta-analysis and current overview. Int J Color Dis. 2015;30(8):1015–28.CrossRef
9.
10.
11.
Sasaki K, Takahashi M, Hashimoto T, et al. Flow cytometric DNA measurement of gastric cancers: clinico-pathological implication of DNA ploidy. Pathol Res Pract. 1989;184(6):561–6.PubMedCrossRef
12.
Wyatt JI, Quirke P, Ward DC, et al. Comparison of histopathological and flow cytometric parameters in prediction of prognosis in gastric cancer. J Pathol. 1989;158(3):195–201.PubMedCrossRef
13.
Baretton G, Carstensen O, Schardey M, et al. DNA-ploidy and survival in gastric carcinomas: a flow-cytometric study. Virchows Archiv A. 1991;418(4):301–9.CrossRef
14.
Filipe MI, Rosa J, Sandey A, et al. Is DNA ploidy and proliferative activity of prognostic value in advanced gastric carcinoma? Hum Pathol. 1991;22(4):373–8.PubMedCrossRef
15.
Kimura H, Yonemura Y. Flow cytometric analysis of nuclear DNA content in advanced gastric cancer and its relationship with prognosis. Cancer. 1991;67(10):2588–93.PubMedCrossRef
16.
Kakeji Y, Maehara Y, Korenaga D, et al. Prognostic significance of tumor-host interaction in clinical gastric cancer: relationship between DNA ploidy and dendritic cell infiltration. J Surg Oncol. 1993;52(4):207–12.PubMedCrossRef
17.
18.
Flyger HL, Christensen IJ, Thorup J, et al. DNA aneuploidy in gastric carcinoma flow cytometric data related to survival, location, and histopathologic findings. Scand J Gastroenterol. 1995;30(3):258–64.PubMedCrossRef
19.
Tsuchiya A, Kikuchi Y, Ando Y, et al. Correlation between expression of sialosyl-T antigen and survival in patients with gastric cancer. BJS. 1995;82(7):960–2.CrossRef
20.
Sakusabe M, Kodama M, Sato Y, et al. Clinical significance of DNA ploidy pattern in stage III gastric cancer. World J Surg. 1996;20(1):27–31.PubMedCrossRef
21.
Victorzon M, Lundin J, Haglund C, et al. A risk score for predicting outcome in patients with gastric cancer, based on stage, sialyl-Tn immunoreactivity and ploidy—a multivariate analysis. Int J Cancer. 1996;67(2):190–3.PubMedCrossRef
22.
Imada T, Yamamoto Y, Fukuzawa K, et al. Flow cytometric analysis of nuclear DNA heterogeneity in gastric cancer. Jpn J Clin Oncol. 1997;27(4):221–6.PubMedCrossRef
23.
Omejc M, Repše S, Bračko M. DNA flow cytometry in gastric carcinoma: implication in patients with potentially curative resection. J Surg Oncol. 1997;65(4):237–41.PubMedCrossRef
24.
Abad M, Rincon MR, Silva I, et al. DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer. Anal Cell Pathol. 1998;16(4):223–31.PubMedPubMedCentralCrossRef
25.
Hirose K, Iida A, Yamaguchi A, et al. Prognostic value of DNA ploidy and proliferating cell nuclear antigen in gastric cancer. Oncology. 1998;55(4):300–6.PubMedCrossRef
26.
Danesi DT, Spanò M, Fabiano A, et al. Flow cytometric DNA ploidy, p53, PCNA, and c-erbB-2 protein expressions as predictors of survival in surgically resected gastric cancer patients. Cytometry Part A. 2000;42(1):27–34.CrossRef
27.
Ikeguchi M, Oka S, Saito H, et al. Nuclear accumulation of p53 protein in gastric cancer strongly correlates with enlargement of nuclear area of cancer cells. Oncol Rep. 2000;7(3):579–663.PubMed
28.
Russo A, Bazan V, Migliavacca M, et al. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma. Cancer. 2001;92(2):294–302.PubMedCrossRef
29.
Wu YF, Xu HM, Chen JQ. Evaluation of the correlations of cell proliferation activity with lymphatic and vascular invasion and prognosis in gastric carcinoma. Zhonghua Zhong Liu Za Zhi. 2005;27(8):492–5.PubMed
30.
Nesi G, Bruno L, Saieva C, et al. DNA ploidy and S-phase fraction as prognostic factors in surgically resected gastric carcinoma: a 7-year prospective study. Anticancer Res. 2007;27(6C):4435–41.PubMed
31.
Wiksten JP, Lundin J, Nordling S, et al. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. Anticancer Res. 2008;28(4C):2279–87.PubMed
32.
Belien JAM, Buffart TE, Gill AJ, et al. Gross genomic damage measured by DNA image cytometry independently predicts gastric cancer patient survival. Br J Cancer. 2009;101(6):1011.PubMedPubMedCentralCrossRef
33.
Syrios J, Sougioultzis S, Xynos ID, et al. Survival in patients with stage IV noncardia gastric cancer-the influence of DNA ploidy and helicobacter pylori infection. BMC Cancer. 2012;12(1):264.PubMedPubMedCentralCrossRef
34.
Nishimura S, Oki E, Ando K, et al. High ubiquitin-specific protease 44 expression induces DNA aneuploidy and provides independent prognostic information in gastric cancer. Cancer Med. 2017;6(6):1453–64.PubMedPubMedCentralCrossRef
35.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedPubMedCentralCrossRef
36.
37.
38.
39.
Danova M, Riccardi A, Mazzini G, et al. Flow cytometric analysis of paraffin-embedded material in human gastric cancer. Anal Quant Cytol Histol. 1988;10(3):200–6.PubMed
40.
Johnson H, Belluco C, Masood S, et al. The value of flow cytometric analysis in patients with gastric cancer. Arch Surg. 1993;128:314.PubMedCrossRef
41.
Esteban F, Garcia R, Rodriguez R, et al. DNA content by flow cytometry in gastric carcinoma: pathology, ploidy and prognosis. Hepatogastroenterology. 1999;46(27):2039–43.PubMed
42.
Korenaga D, Saito A, Baba H, et al. Cytophotometrically determined DNA content, mitotic activity, and lymph node metastasis in clinical gastric cancer. Surgery. 1990;107(3):262–7.PubMed
43.
Macartney JC, Camplejohn RS, Powell G. DNA flow cytometry of histological material from human gastric cancer. J Pathol. 1986;148(4):273–7.PubMedCrossRef
44.
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Apmis. 1965;64(1):31–49.
Metadata
Title
Prognostic value of DNA aneuploidy in gastric cancer: a meta-analysis of 3449 cases
Authors
Jing Xu
Ruolin Zhu
Lulu Fan
Shangqing Ge
Wei Wei
Xiaoqiu Li
Liangshan Da
Zhenya Jia
Zhiyan Zhao
Jie Ning
Jie Da
Wanren Peng
Kangsheng Gu
Guoping Sun
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5869-9

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women

Research article

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial

Research article

Prognostic value of estrogen receptor-α and progesterone receptor in curatively resected colorectal cancer: a retrospective analysis with independent validations

Research article

Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer

Research article

Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer

Case report

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits